日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Macular corneal dystrophy and associated corneal thinning

黄斑角膜营养不良及相关角膜变薄

Dudakova, L; Palos, M; Svobodova, M; Bydzovsky, J; Huna, L; Jirsova, K; Hardcastle, A J; Tuft, S J; Liskova, P

Severe Meesmann's epithelial corneal dystrophy phenotype due to a missense mutation in the helix-initiation motif of keratin 12

角蛋白12螺旋起始基序中的错义突变导致严重的梅斯曼氏上皮角膜营养不良表型

Hassan, H; Thaung, C; Ebenezer, N D; Larkin, G; Hardcastle, A J; Tuft, S J

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.

一项针对实体瘤的血管生成抑制剂 SU5416(semaxanib)的 I 期研究,纳入了动态对比 MR 药效学终点

O'Donnell A, Padhani A, Hayes C, Kakkar A J, Leach M, Trigo J M, Scurr M, Raynaud F, Phillips S, Aherne W, Hardcastle A, Workman P, Hannah A, Judson I

RPGR mutation associated with retinitis pigmentosa, impaired hearing, and sinorespiratory infections

RPGR基因突变与视网膜色素变性、听力障碍和鼻窦呼吸道感染相关

Zito, I; Downes, S M; Patel, R J; Cheetham, M E; Ebenezer, N D; Jenkins, S A; Bhattacharya, S S; Webster, A R; Holder, G E; Bird, A C; Bamiou, D E; Hardcastle, A J

Genotype-phenotype correlation in British families with X linked congenital stationary night blindness

英国X连锁先天性静止性夜盲症家族的基因型-表型相关性

Allen, L E; Zito, I; Bradshaw, K; Patel, R J; Bird, A C; Fitzke, F; Yates, J R; Trump, D; Hardcastle, A J; Moore, A T

In vitro analysis of aminoglycoside therapy for the Arg120stop nonsense mutation in RP2 patients

对RP2患者Arg120stop无义突变进行氨基糖苷类药物治疗的体外分析

Grayson, C; Chapple, J P; Willison, K R; Webster, A R; Hardcastle, A J; Cheetham, M E

Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines

小鼠和三种人细胞系获得对喹唑啉胸苷酸合成酶抑制剂 ZD1694 (Tomudex) 耐药的机制

Jackman, A L; Kelland, L R; Kimbell, R; Brown, M; Gibson, W; Aherne, G W; Hardcastle, A; Boyle, F T